MACE · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in MACE compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Death · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in death compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in all major occlusive vascular events compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in intracerebral haemorrhage (ICH) compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Functional outcomes · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in fnctional status (mRS 0‐2) compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Death or dependence · acute ischaemic stroke
Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).
1 finding from 1 review
Death from any cause during · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes death from any cause during compared with control (very low certainty).
1 finding from 1 review
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Recurrent ischaemic or unknown stroke during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Complete recovery from stroke (post hoc) · acute ischaemic stroke
Antiplatelet drug probably leads to higher complete recovery from stroke (post hoc) compared with control (moderate certainty).
1 finding from 1 review